Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...

Thank you, Briana. Good afternoon, and welcome to Tempus’ third quarter 2024 conference call. This afternoon, Tempus released results for the quarter ending September 30, 2024. Joining me today from ...

We examine the top 10 blue-chip losers to date and potential ... vaccine Comirnaty (in collaboration with German biotech BioNTech). The business’s post-pandemic performance has sometimes been ...

Stock futures were mostly higher Monday, kicking off a week that includes the election for U.S. president and and a decision on interest rates from the Federal Reserve.These stocks were poised to make ...

We examine the top 10 blue-chip losers to date and potential ... vaccine Comirnaty (in collaboration with German biotech BioNTech). The business’s post-pandemic performance has sometimes been ...

the result of a bid to strike it down filed by BioNTech. The invalidation has come out of the blue for CureVac, which said earlier in the year that the patent court had supported its position in ...

BioNTech lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and ...

The global mRNA synthesis and manufacturing market is projected to grow from USD 2,231.4 million in 2024 to USD 2,958.3 ...